Condition: AChR-Ab Seropositive Generalized Myasthenia Gravis · Myasthenia Gravis · Sponsor: argenx
This study is part of the ADAPT Forward platform study (NCT07294170). ADAPT Forward is a platform study with the aim to look at how safe different drugs are and how well they work for people with myasthenia gravis. The goal is to find the best therapeutic approach to reduce patients' side effects and improve their quality of life. The aim of this ISA1 is to evaluate the safety and therapeutic relevance of empasiprubart as add-on therapy to efgartigimod in participants with AChR-Ab seropositive generalized myasthenia gravis. The ADAPT Forward master protocol is registered on https://clinicaltrials.gov/study/NCT07294170
This description comes directly from the study's public registry record.
Sabine Coppieters, MD · 857-350-4834 · clinicaltrials@argenx.com
Always discuss trial participation with your own doctor first.
| Profound Research LLC - Carlsbad | Carlsbad, California, United States | Recruiting |
| Visionary Investigators Network | Miami, Florida, United States | Recruiting |
| University of South Florida | Tampa, Florida, United States | Recruiting |
| Henry Ford Health Systems | Detroit, Michigan, United States | Active Not Recruiting |
| Dent Neurologic Institute - Amherst | Amherst, New York, United States | Recruiting |
| Duke Early Phase Clinical Research Unit - PPDS | Durham, North Carolina, United States | Active Not Recruiting |
| Ohio State Martha Morehouse Outpatient Care | Columbus, Ohio, United States | Recruiting |
| Erlanger Health System | Chattanooga, Tennessee, United States | Recruiting |
| National Neuromuscular Research Institute | Austin, Texas, United States | Recruiting |
| University of Texas- San Antonio - Health Science Center - PPDS | San Antonio, Texas, United States | Recruiting |
| UZ Leuven - PPDS | Leuven, Belgium | Recruiting |
| ASST Papa Giovanni XXIII - Ospedale Papa Giovanni XXIII | Bergamo, Lombardy, Italy | Recruiting |
+ 3 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07284420